MYOMO, INC. (MYO)

MyoMo manufactures wearable robotic braces that restore arm and hand function to patients with stroke, upper-limb paralysis, or neuromuscular weakness. Trading under the ticker MYO and registered with the SEC under CIK 1369290, MyoMo sits at the intersection of medical devices, robotics, and neurorehabilitation—a niche but growing market where even modest improvements in arm function can dramatically improve a patient’s quality of life and independence.

What the Device Does

MyoMo’s core product is called MyoMo Assist Glove (formerly called MyoMo ME). It is a lightweight, battery-powered brace worn on the forearm and hand. Embedded in the glove are electromyography sensors that detect electrical signals from residual muscles—tiny muscle contractions that a stroke or paralyzed patient can still produce but cannot translate into visible hand movement. The device picks up these signals, interprets them using algorithms, and sends a small electric pulse to activate motors that move the fingers and wrist.

The effect is profound. A stroke patient who cannot voluntarily open and close their hand can wear the glove, “think” about opening their hand, and the device detects that intention and moves the fingers. Over months of use, the patient’s own neural circuits may strengthen and re-establish voluntary control. The device becomes both a tool for immediate function and a rehabilitation aid.

MyoMo targets several patient populations. The largest is stroke survivors. Approximately 15 million stroke survivors worldwide have some degree of arm or hand weakness; fewer than 10 percent have recovered full function. Another target is brachial plexus injury (severe shoulder and arm injury from trauma, often seen in motorcycle accidents). A third is patients with progressive neuromuscular disease like ALS or muscular dystrophy, where the glove can compensate for declining strength.

Market Size and Reimbursement

The addressable market is large but fragmented. Roughly 2 million new stroke survivors in the United States each year survive with arm weakness. Rehabilitation is often underfunded; many patients spend weeks in therapy and then return home without continued support. Insurance companies are beginning to recognize that wearable devices can substitute for or extend therapy and improve outcomes, but reimbursement is nascent.

Medicare and commercial insurers cover MyoMo under the category of powered orthotic devices. Reimbursement rates vary by payer but generally fall in the range of $15,000 to $25,000 per device. Patients may also pay out-of-pocket or receive funding through worker’s compensation (if the injury is work-related) or disability programs. MyoMo also markets directly to rehabilitation centers and hospitals, which purchase devices to lend or lease to patients.

Revenue Model and Path to Profitability

MyoMo sells devices directly to healthcare providers, rehabilitation hospitals, and patients. The company also pursues reimbursement from Medicare and insurers to increase coverage and payment rates. Revenue is lumpy—each device sale is a large transaction—making quarter-to-quarter results volatile.

MyoMo is a small-cap, pre-profitability company. It spends heavily on research and development to improve the device, on clinical trials to demonstrate efficacy and safety, and on sales and marketing to expand payer coverage and clinician awareness. The company is burning cash and relies on raising capital through equity offerings or debt.

The path to profitability is narrowing as MyoMo scales. If the company can increase annual unit sales (from hundreds to thousands) and expand payer coverage, gross margin will improve and operating leverage will kick in. But scale is slow; the market is large but fragmented, reimbursement processes are cumbersome, and clinician adoption takes time.

Competitive and Regulatory Landscape

MyoMo faces competition from other wearable robotics companies. Myomo Inc. is a stronger competitor (note the similar name, but different company). Others include Bionik Laboratories and various academic spinouts. The space is not yet winner-take-all; each player targets slightly different indications or geographies.

The FDA regulates powered orthotic devices as medical devices, typically Class II or Class III depending on the specific claim. MyoMo has obtained 510(k) clearance from the FDA for the MyoMo Assist Glove, meaning it demonstrated substantial equivalence to a predicate device. This clears the path to marketing in the United States, but the company must continue to gather clinical evidence to support broader claims and coverage.

Capital Intensity and Funding

Manufacturing and developing a medical device is capital-intensive. MyoMo maintains inventory, operates or contracts manufacturing, and invests in design iterations. The company has raised capital through multiple rounds of venture funding and then a public offering (reverse merger or IPO). The capital structure usually includes debt and equity. Large institutional investors include venture funds focused on healthcare and medical devices.

Barriers to Scale

The main barriers are reimbursement, clinician adoption, and manufacturing. Reimbursement comes slowly—payers demand evidence of cost-effectiveness, and conducting such studies takes years. Clinicians must be convinced that the device improves patient outcomes and is worth the setup time. Manufacturing must scale without compromising quality or increasing per-unit cost so much that the device becomes prohibitively expensive.

How to Research MyoMo

Start with the 10-K. The “Business” section describes the device, the manufacturing process, the regulatory approvals, and the reimbursement landscape. The “Risk Factors” highlight capital needs, reimbursement uncertainty, and competitive threats.

Look for clinical trial results. MyoMo publishes studies on device efficacy in peer-reviewed journals. These papers show whether patients using the device recover arm function faster or to a greater degree than standard rehabilitation alone.

Quarterly earnings reports disclose the number of devices sold or in pilot use with healthcare providers. Growth in device units and expansion into new hospitals or payers are signs of traction.

The company’s cash balance and burn rate (reported in the cash flow statement) tell you how long until MyoMo must raise capital again. If cash is depleting rapidly and reimbursement expansion is slow, the company may face pressure to raise capital at an unfavorable valuation or to be acquired.